Insider Selling: Iradimed Corp (NASDAQ:IRMD) VP Sells 1,000 Shares of Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $21.10, for a total value of $21,100.00. Following the completion of the sale, the vice president now directly owns 2,368 shares of the company’s stock, valued at $49,964.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Brent Johnson also recently made the following trade(s):

  • On Monday, August 12th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $21.27, for a total value of $21,270.00.
  • On Friday, August 9th, Brent Johnson sold 2,400 shares of Iradimed stock. The shares were sold at an average price of $21.81, for a total value of $52,344.00.
  • On Monday, August 5th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $21.94, for a total value of $65,820.00.
  • On Wednesday, August 7th, Brent Johnson sold 7,000 shares of Iradimed stock. The shares were sold at an average price of $21.93, for a total value of $153,510.00.
  • On Friday, August 2nd, Brent Johnson sold 5,000 shares of Iradimed stock. The shares were sold at an average price of $22.83, for a total value of $114,150.00.
  • On Wednesday, July 31st, Brent Johnson sold 8,000 shares of Iradimed stock. The shares were sold at an average price of $22.68, for a total value of $181,440.00.
  • On Monday, July 1st, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.46, for a total value of $20,460.00.
  • On Wednesday, July 3rd, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.16, for a total value of $60,480.00.
  • On Friday, June 28th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $20.53, for a total value of $41,060.00.
  • On Wednesday, June 26th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.34, for a total value of $20,340.00.

Shares of NASDAQ IRMD traded down $0.72 during trading hours on Wednesday, reaching $20.98. 50,628 shares of the stock were exchanged, compared to its average volume of 70,909. The company has a market cap of $238.54 million, a price-to-earnings ratio of 48.79 and a beta of 1.65. The company has a quick ratio of 9.39, a current ratio of 10.29 and a debt-to-equity ratio of 0.06. Iradimed Corp has a 52 week low of $16.68 and a 52 week high of $38.78. The company’s fifty day simple moving average is $19.95.

Several hedge funds and other institutional investors have recently made changes to their positions in IRMD. Oppenheimer Asset Management Inc. bought a new position in Iradimed during the 1st quarter worth $76,000. Victory Capital Management Inc. bought a new position in Iradimed during the 1st quarter worth $212,000. Charles Schwab Investment Management Inc. increased its stake in Iradimed by 34.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 10,500 shares of the medical equipment provider’s stock worth $215,000 after acquiring an additional 2,666 shares during the period. Marshall Wace LLP bought a new position in Iradimed during the 1st quarter worth $241,000. Finally, Morgan Stanley increased its stake in Iradimed by 14.3% during the 2nd quarter. Morgan Stanley now owns 13,118 shares of the medical equipment provider’s stock worth $268,000 after acquiring an additional 1,637 shares during the period. Institutional investors own 23.49% of the company’s stock.

IRMD has been the topic of a number of recent research reports. BidaskClub lowered Iradimed from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Zacks Investment Research lowered Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. Finally, ValuEngine upgraded Iradimed from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $31.50.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

See Also: Fundamental Analysis

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply